Advertisement

Disappearing colorectal liver metastases in the era of state-of-the-art triple-modality diagnostic imaging

Published:January 11, 2023DOI:https://doi.org/10.1016/j.ejso.2023.01.011

      Abstract

      Introduction

      Systemic therapy can result in disappearance of colorectal liver metastases in up to 40% of patients. This might be an overestimation caused by suboptimal imaging modalities. The aim of this study was to investigate the use of imaging modalities and the incidence, management and outcome of patients with disappearing liver metastases (DLMs).

      Methods

      This was a retrospective study of consecutive patients treated for colorectal liver metastases at a high volume hepatobiliary centre between January 2013 and January 2015 after receiving induction or neoadjuvant systemic therapy. Main outcomes were use of imaging modalities, incidence, management and longterm outcome of patients with DLMs.

      Results

      Of 158 patients included, 32 (20%) had 110 DLMs. Most patients (88%) had initial diagnostic imaging with contrast enhanced-CT, primovist-MR and FDG-PET and 94% of patients with DLMs were restaged using primovist-MR. Patients with DLMs had significantly smaller metastases and the median initial size of DLMs was 10 mm (range 5–61). In the per lesion analysis, recurrence after “watch & wait” for DLMs occurred in 36%, while in 19 of 20 resected DLMs no viable tumour cells were found. Median overall (51 vs. 28 months, p < 0.05) and progression free survival (10 vs. 3 months, p = 0.003) were significantly longer for patients with DLMs.

      Conclusion

      Even state-of-the-art imaging and restaging cannot solve problems associated with DLMs. Regrowth of these lesions occurs in approximately a third of the lesions. Patients with DLMs have better survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leporrier J.
        • et al.
        A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer.
        Br J Surg. 2006; 93: 465-474
        • de Jong M.C.
        • et al.
        Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.
        Ann Surg. 2009; 250: 440-448
        • Fong Y.
        • et al.
        Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
        Ann Surg. 1999; 230 (discussion 318-321): 309-318
        • Folprecht G.
        • et al.
        Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
        Lancet Oncol. 2010; 11: 38-47
        • Groot Koerkamp B.
        • et al.
        Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis.
        J Clin Oncol. 2017; 71 (2016): 834https://doi.org/10.1200/JCO.2016.71.8346
        • Ammori J.B.
        • et al.
        Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
        Ann Surg Oncol. 2013; 20: 2901-2907
        • Chua T.C.
        • et al.
        Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases.
        Ann Surg Oncol. 2010; 17: 492-501
        • Ferrero A.
        • et al.
        Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
        J Gastrointest Surg : Off J Soc Surg Aliment Tract. 2012; 16: 806-814
        • van Vledder M.G.
        • et al.
        Disappearing colorectal liver metastases after chemotherapy: should we be concerned?.
        J Gastrointest Surg : Off J Soc Surg Aliment Tract. 2010; 14: 1691-1700
        • Sturesson C.
        • et al.
        Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities.
        HPB. 2015; 17: 983-987
        • Tanaka K.
        • et al.
        Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases.
        Ann Surg. 2009; 250: 935-942
        • Benoist S.
        • et al.
        Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2006; 24: 3939-3945
        • Adam R.
        • et al.
        Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?.
        J Clin Oncol : Off J Am Soc Clin Oncol. 2008; 26: 1635-1641
        • Elias D.
        • et al.
        Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin.
        Ann Surg Oncol. 2007; 14: 3188-3194
        • Auer R.C.
        • et al.
        Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
        Cancer. 2010; 116: 1502-1509
        • Kuhlmann K.
        • et al.
        Management of disappearing colorectal liver metastases.
        Eur J Surg Oncol. 2016; 42: 1798-1805
        • Robinson P.J.A.
        The effects of cancer chemotherapy on liver imaging.
        Eur Radiol. 2009; 19: 1752-1762
        • Granata V.
        • et al.
        Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection.
        BMC Gastroenterol. 2019; 19
        • van Kessel C.S.
        • et al.
        Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.
        Ann Surg Oncol. 2012; 19: 2805-2813
        • Macera A.
        • et al.
        Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy.
        Eur Radiol. 2013; 23: 739-747
        • Oba A.
        • et al.
        Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography.
        HPB. 2018; 20
        • Arita J.
        • et al.
        Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy.
        Ann Surg Oncol. 2014; 21: S390-S397
        • Park M.J.
        • et al.
        Use of imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging.
        Radiology. 2017; 284: 423-431
        • Tani K.
        • et al.
        Management of disappearing lesions after chemotherapy for colorectal liver metastases: relation between detectability and residual tumors.
        J Surg Oncol. 2018; 117: 191-197
        • Owen J.W.
        • et al.
        Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging.
        HPB. 2016; 18: 296-303
        • Kim S.S.
        • et al.
        Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: is local treatment required?.
        Eur Radiol. 2017; 27: 3088-3096
        • Ivashchenko O.v.
        • et al.
        Clinical implementation of in-house developed MR-based patient-specific 3D models of liver anatomy. vol. 61. European Surgical Research, 2021
        • Zalinski S.
        • Abdalla E.K.
        • Mahvash A.
        • Vauthey J.N.
        A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy.
        Ann Surg Oncol. 2009; 16
        • Melstrom L.G.
        • et al.
        Management of disappearing colorectal liver metastases: an international survey.
        HPB. 2021; 23
        • Muaddi H.
        • et al.
        When is a ghost really gone? A systematic review and meta-analysis of the accuracy of imaging modalities to predict complete pathological response of colorectal cancer liver metastases after chemotherapy.
        Ann Surg Oncol. 2021; 28: 6805-6813